Lead Product(s) : Albendazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr. Reddy's Laboratories Announces the Launch of Albendazole Tablets, USP in the U.S. Market
Details : Albendazole Tablets, USP, a therapeutic equivalent generic version of Albenza Tablets, 200 mg, approved by the U.S. Food and Drug Administration. Dr. Reddy’s Albendazole Tablets, USP are available in 200 mg tablets in bottle count sizes of two.
Product Name : Albendazole-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 29, 2021
Lead Product(s) : Albendazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Albendazole
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Albendazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Intestinal Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 11, 2024
Lead Product(s) : Albendazole
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Albendazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Leiden University Medical Center | Bahir Dar University | Centro de Investigacao em Saude de Manhica | London School of Hygiene & Tropical Medicine | Kenya Medical Research Institute | Laboratorios Liconsa | Universidad de León | European & Developing Cou
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Albendazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Intestinal Helminthiasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 18, 2021
Lead Product(s) : Albendazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Leiden University Medical Center | Bahir Dar University | Centro de Investigacao em Saude de Manhica | London School of Hygiene & Tropical Medicine | Kenya Medical Research Institute | Laboratorios Liconsa | Universidad de León | European & Developing Cou
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
